Equity Sector Funds Very High Risk
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | 7.91% | 7.54% | 0.1% | -2.35% | 8.33% | 14.29% | 24.87% | 17.09% | 13.99% | 12.81% | 14.66% |
| Category returns | 6.83% | 7.45% | 0.03% | -2.3% | 6.38% | 11.92% | 22.96% | 16.06% | 13.74% | 12.95% | N/A |
| Absolute returns | 7.88% | 8.92% | 6.92% | 4.14% | 13.1% | 36.71% | 107.54% | 110.43% | 95.58% | 233.79% | 3956.23% |
| Rank within category | 6 | 8 | 9 | 10 | 5 | 3 | 2 | 3 | 4 | 2 | N/A |
| Total Schemes in Category | 18 | 18 | 17 | 17 | 16 | 14 | 10 | 10 | 9 | 4 | N/A |
| Sector Funds | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yearly returns | -9.71% | 6.2% | -7.53% | 1.18% | 67.36% | 19.09% | -12.32% | 38.2% | 42.86% | -3.15% | 8.41% |
| Q1 returns | -8.84% | 4.72% | -9.45% | 2.55% | -5.72% | -2.01% | -7.3% | -3.44% | 8.85% | -8.51% | -4.49% |
| Q2 returns | 3.78% | -5.81% | 0.31% | -7.94% | 30.58% | 18.4% | -10.89% | 15.14% | 5.37% | 6.66% | 13.5% |
| Q3 Returns | 4.22% | -2.52% | 7.9% | -1.66% | 24.11% | 3.3% | 7.28% | 12.49% | 23.11% | -0.62% | N/A |
| Q4 Returns | -8.43% | 10.45% | -5.64% | 8.97% | 9.54% | -0.64% | -1.06% | 10.5% | 1.18% | -0.12% | N/A |
Expense ratio: 2.3%
Inclusive of GST
Exit load
1% on or before 30D, Nil after 30D
| Alpha | 1.20527 |
| Beta | 0.6957 |
| Sharpe Ratio | 0.365984 |
| Sortino Ratio | 0.810384 |
| R-Squared | 0.3346 |
| Tracking Error | 3.5923 |
| Downside Risk | 16.2254 |
| Std. Deviation (Annualised) | 14.5775 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth | 9.18% | 6.67% | -0.99% | -3.59% | 7.1% | 27.02% | 16.23% | 0% | 19.44% | 6,293.14 | 1.87 | 0.39 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW Current | 7.91% | 7.54% | 0.1% | -2.35% | 8.33% | 24.87% | 13.99% | 12.81% | 14.66% | 1,055.53 | 2.28 | 0.35 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | 5.71% | 8.21% | 0.45% | -1.13% | 4.56% | 24.83% | 15.56% | 12.3% | 16.26% | 4,063.64 | 1.93 | 0.37 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | 6.15% | 10.25% | 3.03% | 0.11% | 9.4% | 23.81% | 14.41% | 0% | 19.42% | 2,753.72 | 1.94 | 0.34 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | 4.7% | 6.4% | 1.22% | -1.71% | 5.37% | 22.75% | 12.57% | 0% | 18.41% | 858.87 | 2.30 | 0.33 | Very High |
| Nippon India Pharma Fund - Growth | 5.58% | 6.09% | 0.67% | -3.68% | 4.04% | 22.1% | 13.33% | 14.48% | 19.73% | 7,898.24 | 1.82 | 0.32 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | 6.85% | 5.21% | -3.15% | -4.34% | 2.3% | 22.03% | 13.39% | 12.21% | 11.21% | 1,229.42 | 2.15 | 0.30 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | 8.21% | 4.38% | -0.83% | -4.8% | 4.87% | 21.77% | 13.64% | 0% | 20.1% | 2,891.76 | 1.94 | 0.31 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | 7.33% | 7.14% | -1.96% | -3.4% | 4.69% | 20.94% | 10.57% | 0% | 16.19% | 78.30 | 2.36 | 0.29 | Very High |
| ITI Pharma & Healthcare Fund - Regular Plan - Growth | 8.1% | 8.47% | -2.98% | -5.82% | 0.32% | 19.48% | 0% | 0% | 10.95% | 211.30 | 2.35 | 0.25 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 95.25% |
| Cash & Cash Equivalents and Net Assets | 4.74% | |
| Deposits (Placed as Margin) | 0.01% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 68.83% | |
| Others | 4.75% | |
| Healthcare Services | 23.45% | |
| Chemicals & Petrochemicals | 1.99% | |
| Healthcare Equipment & Supplies | 0.98% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.49% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.84% |
| NET CURRENT ASSETS | Cash & Cash Equivalents and Net Assets | 4.74% | |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.23% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 3.54% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.45% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.35% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.35% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.30% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 3.23% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.21% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 3.00% |
| Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.96% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.48% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.46% |
| Procter & Gamble Health Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.28% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.19% |
| Caplin Point Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.17% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.15% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 2.06% |
| Sudeep Pharma Ltd. | Chemicals & Petrochemicals | Domestic Equities | 1.99% |
| Aster DM Healthcare Ltd. | Healthcare Services | Domestic Equities | 1.99% |
| Viyash Scientific Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.95% |
| Jupiter Life Line Hospitals Ltd. | Healthcare Services | Domestic Equities | 1.94% |
| Marksans Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.83% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.72% |
| Metropolis Healthcare Ltd. | Healthcare Services | Domestic Equities | 1.61% |
| Rainbow Children's Medicare Ltd. | Healthcare Services | Domestic Equities | 1.58% |
| Eris Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.56% |
| Pfizer Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.47% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 1.34% |
| Vijaya Diagnostic Centre Ltd. | Healthcare Services | Domestic Equities | 1.31% |
| Windlas Biotech Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.23% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 1.20% |
| Emcure Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.02% |
| Sanofi Consumer Healthcare India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.01% |
| Laxmi Dental Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.98% |
| Aarti Pharmalabs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.97% |
| Jubilant Pharmova Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.73% |
| Alembic Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.68% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 0.67% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.63% |
| Acutaas Chemicals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.57% |
| Orchid Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.55% |
| CLEARING CORPORATION OF INDIA LTD. STD - MARGIN | Deposits (Placed as Margin) | 0.01% | |
| Total | 100.00% |
RETURNS
It is an Open ended scheme that primarily invests in Sector Funds.
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
The scheme benchmark is the BSE Health Care - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 13.09%
3-year: 27.53%
5-year: 14.35%
Top holdings include names such as:
The NAV is around ₹237.92 (approx.) for the UTI Healthcare Fund - Regular Plan - IDCW.
The fund’s AUM is approximately ₹1,144 Cr.
The expense ratio for the Regular Plan is 2.3.
1% on or before 30D, Nil after 30D.
Minimum SIP starts at ₹1000.
The minimum lump sum investment is ₹5000. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund manager: Kamal Gada
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
